In patients with obesity, the effect of VLCKD is powerful in reducing plasma insulin levels; consequently, HOMA-IR and HOMA-beta, which represent markers of insulin resistance and beta-cell function, respectively, display significant improvements after this dietetic intervention [71, 72]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.